Srinivas Rao

Atai Life Sciences (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on mental health innovation, announced its third-quarter 2024 financial results Wednesday as well as updates on its clinical and corporate strategies. With notable advancements in its investigational programs, the...

Psychedelics have shown promise in treating various mental health issues, including PTSD and depression, but they’ve often faced notable challenges. Side effects like nausea, cardiovascular risks, and the potential for "bad trips" have raised concerns among both clinicians and patients. As...

Atai Life Sciences (NASDAQ:ATAI) announced promising preliminary results on Tuesday for its DMT-based depression therapy, VLS-01. As BioSpace reported, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with treatment-...

Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc. (NYSE: HTGC). The company...

The Week In Psychedelics Atai Launches ‘Precision Psychiatry’ Subsidiary The Psychedelics Sector Reaches 50 Public Companies Listed In The U.S. Pasithea Therapeutics To Launch Its First Ketamine Clinic In The UK PharmaTher Receives FDA Orphan Drug Designation For Ketamine...

Atai Life Sciences t announced on Tuesday a new research collaboration with Massachusetts General Hospital, the largest teaching hospital of Harvard Medical School. The partnership will help advance the hospital’s Center for Neuroscience of Psychedelics, a recently-launched center...

Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol...

Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications. EmpathBio will be a wholly owned subsidiary of ATAI, led by CEO...

In February 2020, scientists in Brazil performed an open-label study on arketamine, a variant of ketamine. The pilot trial, conducted by the Federal University of Bahia, was performed on seven subjects suffering from treatment-resistant depression. It found evidence that arketamine might produce...

With a growing public acceptance of cannabis in society, there's a natural instinct to wonder about the possible health benefits and market potential of other still-illegal substances. “To me, all the psychedelic stuff, it's just prohibition 2.0,” Bruce Linton, cannabis...